Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S. Datoo, Nsajigwa Misidai, Alassane Dicko et al.|The Lancet|2024Cited by 345
Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trialAlassane Dicko, Teun Bousema, Kalifa Diarra et al.|The Lancet Infectious Diseases|2018Cited by 126
Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment TrialIngrid Chen, Alassane Dicko, Halimatou Diawara et al.|The Journal of Infectious Diseases|2018Cited by 27
Persistence of mRNA indicative of Plasmodium falciparum ring-stage parasites 42 days after artemisinin and non-artemisinin combination therapy in naturally infected MaliansAlmahamoudou Mahamar, Michelle E. Roh, Kjerstin Lanke et al.|Malaria Journal|2021Cited by 7